Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 15709206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.

  2004cited by this paper
• Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins

  2004cited by this paper
• Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer.

  2004cited by this paper
• Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia.

  2004cited by this paper
• Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.

  2004cited by this paper
• Local factors regulating growth and function of human thyroid cells in vitro and in vivo.

  2003cited by this paper
• Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer.

  2003cited by this paper
• Re: “Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors”

  2002cited by this paper
• Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

  2002cited by this paper
• Dual Inhibition of Focal Adhesion Kinase and Epidermal Growth Factor Receptor Pathways Cooperatively Induces Death Receptor-mediated Apoptosis in Human Breast Cancer Cells*

  2002cited by this paper
• Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter.

  2002cited by this paper
• Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

  2002cited by this paper
• Protein kinases — the major drug targets of the twenty-first century?

  2002cited by this paper
• Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors.

  2002cited by this paper
• Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis.

  2002cited by this paper
• Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or Bmp4.

  2001cited by this paper
• N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001influential reference
• A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells.

  2001cited by this paper
• Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

  2000cited by this paper
• Medullary Carcinoma of the Thyroid Gland

  2000cited by this paper
• The FGFR1 Inhibitor PD 173074 Selectively and Potently Antagonizes FGF‐2 Neurotrophic and Neurotropic Effects

  2000cited by this paper
• Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures.

  1999cited by this paper
• Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain

  1998cited by this paper
• Differential Expression of the Fibroblast Growth Factor Receptor (FGFR) Multigene Family in Normal Human Adult Tissues

  1997cited by this paper
• GDNF–Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-α, a Novel Receptor for GDNF

  1996cited by this paper
• Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC

  1994cited by this paper
• Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

  1994cited by this paper
• The ins and outs of fibroblast growth factors.

  1994cited by this paper
• Reoperation for recurrent or persistent medullary thyroid cancer.

  1993cited by this paper
• Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A

  1993cited by this paper
• FGFR‐4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern.

  1991cited by this paper
• Medullary carcinoma of the thyroid gland.

  1965cited by this paper

• Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system

  2024cites this paper
• FGFR families: biological functions and therapeutic interventions in tumors

  2023cites this paper
• Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

  2022cites this paper
• Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer

  2022cites this paper
• Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy

  2020cites this paper
• Mouse Models of Thyroid Cancer: Bridging Pathogenesis and Novel Therapeutics.

  2020cites this paper
• Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study

  2020cites this paper
• PD173074 blocks G1/S transition via CUL3-mediated ubiquitin protease in HepG2 and Hep3B cells

  2020cites this paper
• Dysregulation in IGF-1 R , FGFR 4 and β Klotho signaling in patients with medullary thyroid cancer

  2019cites this paper
• The roles and role-players in thyroid cancer angiogenesis.

  2019cites this paper
• Investigating the expression and promoter methylation of RET gene in patients with medullary thyroid cancer with unmutated RET

  2019cites this paper
• Inhibition of FGF Receptor-1 Suppresses Alcohol Consumption: Role of PI3 Kinase Signaling in Dorsomedial Striatum

  2019cites this paper
• The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice

  2018cites this paper
• Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer

  2018cites this paper
• Assessment of fibroblast growth factor receptor cancer-associated mutations and characterisation of endocrine signalling complexes

  2018cites this paper
• Novel targeted therapeutics for MEN2.

  2018cites this paper
• Targeted Therapy for Medullary Thyroid Cancer: A Review

  2017cites this paper
• Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases

  2017cites this paper
• Lenvatinib: Role in thyroid cancer and other solid tumors.

  2016cites this paper
• The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer

  2016cites this paper
• Systemic treatment and management approaches for medullary thyroid cancer.

  2016cites this paper
• The evolving field of kinase inhibitors in thyroid cancer.

  2015cites this paper
• Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

  2014cites this paper
• Update on medullary thyroid cancer.

  2014cites this paper
• Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations.

  2014cites this paper
• Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.

  2013cites this paper
• Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.

  2013cites this paper
• Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma

  2013cites this paper
• New Diagnostic and Therapeutic Tools for Thyroid Cancer

  2013cites this paper
• Targeting the fibroblast growth factor receptors for the treatment of cancer.

  2013cites this paper
• Fibroblast Growth Factor Receptor-2 Expression in Thyroid Tumor Progression: Potential Diagnostic Application

  2013cites this paper
• Prognostic and Predictive Markers in Medullary Thyroid Carcinoma

  2012cites this paper
• PAX3‐FOXO1 and FGFR4 in alveolar rhabdomyosarcoma

  2012cites this paper
• Fibroblast growth factor signaling in ovarian cancer

  2012cites this paper
• Identifying thyroid stem/progenitor cells: advances and limitations.

  2012cites this paper
• FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma

  2012cites this paper
• Anti-tumor activity of motesanib in a medullary thyroid cancer model

  2011cites this paper
• Cancer Therapy : Preclinical Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells

  2011cites this paper
• Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells

  2011cites this paper
• Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy

  2011cites this paper
• Running title: The search for thyroid-stem/progenitor cells

  2011cites this paper
• Molecular Targeted Therapies of Medullary Thyroid Carcinoma

  2011cites this paper
• Development of RET kinase inhibitors for targeted cancer therapy.

  2011cites this paper
• Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine.

  2011cites this paper
• Medullary thyroid cancer: a promising model for targeted therapy.

  2010cites this paper
• FGFR 4 Arg 388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer

  2010cites this paper
• FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.

  2010cites this paper
• Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity.

  2010cites this paper
• Sporadic medullary thyroid cancer.

  2010cites this paper
• The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.

  2010cites this paper
• A Requirement for FGF Signalling in the Formation of Primitive Streak-Like Intermediates from Primitive Ectoderm in Culture

  2010cites this paper
• Carcinogenesis and therapeutic strategies in thyroid cancer.

  2010cites this paper
• Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

  2010cites this paper
• De-regulated FGF receptors as therapeutic targets in cancer.

  2010influential citation
• Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.

  2009cites this paper
• PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[18F]F-L-DOPA

  2009cites this paper
• Medullary Thyroid Cancer: Molecular Biology and Novel Molecular Therapies

  2009cites this paper
• Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma

  2009cites this paper
• Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.

  2009cites this paper
• Investigation of the effects of injury upon intracellular signalling pathways and expression of inflammatory response genes in articular cartilage.

  2009cites this paper
• FibroblastGrowthFactor-RegulatedPalmitoylationofthe NeuralCellAdhesionMoleculeDeterminesNeuronal Morphogenesis

  2008cites this paper
• New therapeutic approaches to treat medullary thyroid carcinoma

  2008cites this paper
• Discovery of dominant and dormant genes from expression data using a novel generalization of SNR for multi-class problems

  2008cites this paper
• Recent advances in thyroid cancer.

  2008cites this paper
• Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment.

  2008cites this paper
• Receptor tyrosine kinase inhibitors in thyroid cancer.

  2008cites this paper
• Fibroblast Growth Factor-Regulated Palmitoylation of the Neural Cell Adhesion Molecule Determines Neuronal Morphogenesis

  2008influential citation
• A fuzzy rule based approach to identify biomarkers for diagnostic classification of cancers

  2007cites this paper
• Dysregulation of stem cell signaling network due to germline mutation, SNP, helicobacter pylori infection, epigenetic change, and genetic alteration in gastric cancer

  2007cites this paper
• AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor

  2007cites this paper
• Sodium/iodide symporter regulation by oncogenes in the mammary gland and thyroid gland using mouse models

  2007cites this paper
• Recent advances in treatment of medullary thyroid carcinoma.

  2007cites this paper
• New multitargeted treatments with antiangiogenic and antitumor activity: focus on sunitinib

  2007cites this paper
• Bedeutung des FGFR4 Polymorphismus in der Pathogenese und Progression von Tumorerkrankungen

  2007cites this paper
• Fgfr4 favorise la résistance des cellules cancéreuses en réponse aux médicaments chimiothérapiques

  2007cites this paper
• Genetic Alterations in Thyroid Cancer: The Role of Mouse Models

  2007cites this paper
• Discovering biomarkers from gene expression data for predicting cancer subgroups using neural networks and relational fuzzy clustering

  2007cites this paper
• Mise au point Recent advances in treatment of medullary thyroid carcinoma ☆

  2007cites this paper
• Le carcinome médullaire de la thyroïde : les nouvelles approches thérapeutiques

  2007cites this paper
• A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.

  2007cites this paper
• In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer

  2006cites this paper
• Cross-talk of WNT and FGF signaling pathways at GSK3ß to regulate ß-catenin and SNAIL signaling cascades

  2006cites this paper
• Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

  2006cites this paper
• Doctorate Program in Molecular Oncology and Endocrinology

  2006cites this paper
• Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy

  2006cites this paper
• FGF signaling network in the gastrointestinal tract (review).

  2006cites this paper
• Multiple Endocrine Neoplasia: Paediatric Perspective

  2005cites this paper
• Multiple endocrine neoplasias in the era of translational medicine.

  2005cites this paper
• Multiple Endocrine Neoplasias in the Era of Translational Medicine

  2005cites this paper
• RET tyrosine kinase signaling in development and cancer.

  2005cites this paper
• Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

  2005cites this paper
• Medullary thyroid cancer: Medical management and follow-up

  2005cites this paper
• Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells

  2005cites this paper